Swedish Orphan Biovitrum AB (publ)
OTC:BIOVF
Intrinsic Value
Swedish Orphan Biovitrum AB engages in the research, development, manufacture, and sale of pharmaceutical. [ Read More ]
The intrinsic value of one
BIOVF
stock under the Base Case scenario is
29.11
USD.
Compared to the current market price of 22.87 USD,
Swedish Orphan Biovitrum AB (publ)
is
Undervalued by 21%.
Swedish Orphan Biovitrum AB (publ)'s market capitalization is 95.3B SEK.
BIOVF stock price is 22.87 USD.
BIOVF stock price (22.87 USD) is 21% less than its Intrinsic Value (29.11 USD).
BIOVF stock price (22.87 USD) is 25% less than its Relative Value (30.5 USD). Open Relative Valuation
BIOVF.
BIOVF's ROIC (Return on Invested Capital) has decreased in the last 3 years from 7% to 6%.
BIOVF's ROE (Return on Equity) for the past 12 months is positive and is equal to 8%.
BIOVF has positive three-year average ROE (Return on Equity): 12%. The company is efficient at transforming stockholders' equity into net income.
BIOVF's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 6%.
BIOVF's Revenue has grown by 18% over the past 12 months.
BIOVF has positive Net Income for the last twelve months.
BIOVF's ROE (Return on Equity) has decreased in the last 3 years from 14% to 8%.
BIOVF has positive three-year average ROIC (Return on Invested Capital): 7%. The company is efficient at using invested capital to generate operating income.
BIOVF's Revenue is forecast to grow at a rate of 12% per year over the next 3 years.
BIOVF's Revenue has been growing by 13% per year for the last 3 years.
BIOVF has positive Operating Income for the last twelve months.
BIOVF's Altman Z-Score is equal to 2.07.
BIOVF has negative Free Cash Flow for the last twelve months.
BIOVF's long-term assets (74B SEK) exceed its long-term liabilties (40B SEK).
BIOVF's short-term liabilties (19B SEK) exceed its short-term assets (13B SEK).
BIOVF has positive Gross Profit for the last twelve months.
BIOVF's D/E (Debt to Equity) is very low and is equal to 0.34.
BIOVF has positive Net Debt. This means that the company has more debt (12B SEK) than cash and short-term investments (904m SEK).
BIOVF generates enough operating income (5B SEK) to cover interest payments on its debt (949m SEK).
Valuation Backtest
Swedish Orphan Biovitrum AB (publ)
Run backtest to discover the historical profit from buying and selling
BIOVF
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Swedish Orphan Biovitrum AB (publ)
Balance Sheet Decomposition
Swedish Orphan Biovitrum AB (publ)
| Current Assets | 12.7B |
| Cash & Short-Term Investments | 904m |
| Receivables | 5.8B |
| Other Current Assets | 6B |
| Non-Current Assets | 61.4B |
| Long-Term Investments | 142m |
| PP&E | 251m |
| Intangibles | 60.1B |
| Other Non-Current Assets | 843m |
| Current Liabilities | 19.1B |
| Accounts Payable | 1B |
| Accrued Liabilities | 5.2B |
| Other Current Liabilities | 12.8B |
| Non-Current Liabilities | 21.1B |
| Long-Term Debt | 11.5B |
| Other Non-Current Liabilities | 9.5B |
Earnings Waterfall
Swedish Orphan Biovitrum AB (publ)
|
Revenue
|
22.1B
SEK
|
|
Cost of Revenue
|
-5B
SEK
|
|
Gross Profit
|
17.2B
SEK
|
|
Operating Expenses
|
-12.5B
SEK
|
|
Operating Income
|
4.7B
SEK
|
|
Other Expenses
|
-2.3B
SEK
|
|
Net Income
|
2.4B
SEK
|
Free Cash Flow Analysis
Swedish Orphan Biovitrum AB (publ)
BIOVF Profitability Score
Profitability Due Diligence
Swedish Orphan Biovitrum AB (publ)'s profitability score is 58/100. The higher the profitability score, the more profitable the company is.
Score
Swedish Orphan Biovitrum AB (publ)'s profitability score is 58/100. The higher the profitability score, the more profitable the company is.
BIOVF Solvency Score
Solvency Due Diligence
Swedish Orphan Biovitrum AB (publ)'s solvency score is 40/100. The higher the solvency score, the more solvent the company is.
Score
Swedish Orphan Biovitrum AB (publ)'s solvency score is 40/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BIOVF Price Targets Summary
Swedish Orphan Biovitrum AB (publ)
According to Wall Street analysts, the average 1-year price target for
BIOVF
is 28.69 USD
with a low forecast of 23.48 USD and a high forecast of 44.1 USD.
Shareholder Return
SOBI Price
Swedish Orphan Biovitrum AB (publ)
| Average Annual Return | 7.23% |
| Standard Deviation of Annual Returns | 11.23% |
| Max Drawdown | -46% |
| Market Capitalization | 95.6B SEK |
| Shares Outstanding | 339 627 008 |
| Percentage of Shares Shorted |
N/A
|
BIOVF News
Last Important Events
Swedish Orphan Biovitrum AB (publ)
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Swedish Orphan Biovitrum AB (publ)
Company Profile
Swedish Orphan Biovitrum AB (publ)
Country
Industry
Market Cap
Dividend Yield
Description
Swedish Orphan Biovitrum AB engages in the research, development, manufacture, and sale of pharmaceutical. The company is headquartered in Solna, Stockholm and currently employs 1,559 full-time employees. The company went IPO on 2006-09-15. The firm develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the Partner Products segment offers about 40 pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The firm has subsidiaries in Sweden, Denmark, Finland, Norway, United Kingdom and France, among others. On September 9, 2013, the Company acquired the full rights to develop and commercialize Kineret (anakinra) from Amgen, the biotechnology company based in the United States.
Contact
IPO
Employees
Officers
The intrinsic value of one
BIOVF
stock under the Base Case scenario is
29.11
USD.
Compared to the current market price of 22.87 USD,
Swedish Orphan Biovitrum AB (publ)
is
Undervalued by 21%.
You don't have any saved screeners yet
